AtishDipankarChoudhuryMD

Oncology • Boston, MA

Genitourinary Oncology, Hematologic Oncology

Senior Physician, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School

Join to view full profile

Dr. Choudhury is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Choudhury's full profile

Already have an account?

Office
450 Brookline Ave
Da930
Boston, MA 02215
Phone+1 617-632-6328

Fax+1 617-632-2165

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012
Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2008
Columbia University Vagelos College of Physicians and SurgeonsClass of 2006

Certifications & Licensure

NH State Medical License 2024 - 2026
RI State Medical License 2022 - 2026
MA State Medical License 2009 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2019 May 29
Active, not recruiting
Phase 2
Abemaciclib With or Without Atezolizumab for mCRPC Start of enrollment: 2021 Aug 20
Active, not recruiting
Phase 2
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC Start of enrollment: 2021 Jun 28
Active, not recruiting
Phase 1
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) Start of enrollment: 2022 Nov 21
Active, not recruiting
Phase 2
Roles: Study Chair, Contact
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) Start of enrollment: 2024 Aug 01
Not yet recruiting
Phase 2
Roles: Contact, Principal Investigator, Sponsor-Investigator
Join now to see all

Publications & Presentations

PubMed

Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase...
Matthew S Robertson, Yating Wang, SuChun Cheng, Hyesun Park, Shahar Glomski
La Radiologia Medica. 2024-11-20
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer.
Praful Ravi, Caiwei Zhong, Wanling Xie, Emma Kelly, Bridget Whelpley
European Urology Oncology. 2024-11-14
2 citations
Insulin resistance during androgen deprivation therapy in men with prostate cancer.
Shehzad Basaria, Mary-Ellen Taplin, Marie McDonnell, Donald C Simonson, Alexander P Lin
Cancer. 2024-11-01

Journal Articles

Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate Cancer
Heather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation
A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer
Christopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate

Press Mentions

Here Are Warning Signs That Men Age 15-35 Need to Know About Testicular CancerApril 7th, 2023
The Combination of Pembrolizumab and Radium-223 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Atish ChouduryFebruary 26th, 2021